Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT

UNUSUAL PRICE AND TRADING VOLUME MOVEMENT

This announcement is made by Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company has noted the unusual price and trading volume movements of the shares of the Company (the "**Shares**") recently. Having made all such enquiries with respect to the Company as is reasonable in the circumstances, the Board confirms that it is not aware of any reasons for these price and volume movements or of any information which must be announced to avoid a false market in the Company's securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As a commercial stage biotech company, the Company is firmly committed to development of first-in-class and best-in-class cancer therapies for patients in China, the Asia-Pacific region and around the world with strong confidence and full determination. The Company is accelerating its transformation from a biotech company to a biopharmaceutical company. The Company wishes to clarify and confirm that its business and operation remain normal and unchanged.

As of the date of this announcement, the Company's first-in-class XPO1 inhibitor 希維奧®/XPOVIO® (Selinexor, ATG-010) has been granted marketing approval in four markets, including Mainland China, Australia, South Korea, and Singapore, and recorded a revenue of RMB54.0 million for the six months ended June 30th, 2022, as announced on August 30th, 2022, primarily attributable to the commercial launch of 希維奧®/XPOVIO® in Mainland China on May 13th, 2022. We announced on September 1, 2022 that XPOVIO® is now included for Reimbursement by the Pharmaceutical Benefits Scheme (PBS) in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma, which marks the XPOVIO®'s entering into national reimbursement market in the high-profile APAC markets. The Company is confident in the continued successful commercialization of 希維奧®/XPOVIO® across multiple markets and further approvals in the remaining markets where we have submitted NDAs for. Meanwhile the loss for the period excluding the effect brought by equity-settled share option expense narrowed by RMB83.6 million from RMB209.9 million for the six months ended June 30, 2021 to RMB126.3 million for the six months ended June 30, 2022.

The Company has continued to make clinical and pre-clinical development progress in its robust pipeline of 15 assets with differentiated targets and synergistic mechanisms of action, including 10 assets with wholly owned global rights, including ATG-017 (ERK 1/2 inhibitor), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-037 (CD73 inhibitor), ATG-031 (CD24 monoclonal antibody), ATG-018 (ATR inhibitor) and ATG-022 (Claudin 18.2 ADC). Among them, the Company has observed encouraging efficacy and safety profiles pre-clinically and has published some of these results at the Society for Immunotherapy of Cancer's 36th Annual Meeting & Pre-Conference Programs (SITC 2021), and the American Association for Cancer Research Annual Meeting 2022 (AACR 2022).

Over the past few months, the Company has made significant progress in the clinical development front. In May 2022, the Company dosed the first patient in China in the Phase I/II SWATCH study of ATG-010 (selinexor) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) and relapsed/refractory indolent non-Hodgkin lymphoma (rriNHL). In June 2022, the Company dosed the first patient in Australia in the Phase I STAMINA study of ATG-037 (CD73 inhibitor) in patients with locally advanced or metastatic solid tumors. Furthermore, the Company has kicked start two clinical trials in August 2022, including the Phase I PROBE-CN study of ATG-101 (PD-L1/4-1BB bispecific antibody) in China, and the ATRIUM study of ATG-018 (ATR inhibitor) in Australia.

The Company also advanced in business development, including forming a clinical trial collaboration with BeiGene, Ltd. in the first half of 2022, and a research collaboration with a cell therapy company, Celularity Inc. (NASDAQ: CELU), in July 2022.

With deep research and development capabilities, the Company will continue to be committed to global innovation and build a high-potential product portfolio that drives company value with transformational growth prospects.

Shareholders and potential investors of the Company are advised to exercise caution in dealing with the Shares.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, September 6, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald Andrew Lung and Dr. Kevin P. Lynch as executive directors; Mr. Yilun Liu and Dr. Kan Chen as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for cancer and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 24 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for selinexor/ATG-010/XPOVIO® in mainland China, South Korea, Singapore, Australia and Hong Kong approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. Antengene has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company's Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange.